# Omnicell account plan

> Omnicell is a US medication management automation company for hospitals and pharmacies, with $1,184.8 million of revenue in 2025.

## At a glance

Omnicell (NASDAQ: OMCL), headquartered in Fort Worth, Texas, sells medication dispensing automation, robotics, consumables, software and services to hospitals, health systems and outpatient, institutional and retail pharmacies. It reports one segment and targets the Autonomous Pharmacy, a vision of zero-error medication management, through its Titan XT cabinets and the cloud-native OmniSphere platform. In 2025 total revenues were $1,184.8 million (+7%), net income $2.1 million and ARR $636 million; about 90% of revenue came from the United States. It had about 3,580 employees at the end of 2025 and about 3,450 at September 30, 2026.

## Business units

- **Connected devices, software licenses, and other** (about 48% of 2025 revenue ($565.5 million, computed)): Point of Care automated dispensing (XT Series and the next-generation Titan XT), Central Pharmacy robotics, IV compounding hardware and medication adherence packaging automation. XTExtend console upgrades drove 2025 growth; product backlog was $640.3 million at year-end 2025.
- **Consumables** (about 8% of 2025 revenue ($100.2 million, computed)): Single-dose and multi-medication blister packaging for institutional pharmacies serving long-term care and for retail and outpatient pharmacies. Q3 2026 consumables revenue was $26.9 million against $24.9 million a year earlier.
- **Technical services** (about 22% of 2025 revenue ($260.1 million, computed)): Post-installation support, maintenance, field service, parts and software upgrades, with US support centers staffed 24 hours a day. It grew $21.9 million in 2025 on a larger installed base and pricing actions.
- **SaaS and Expert Services** (about 22% of 2025 revenue ($259.1 million, computed)): Specialty Pharmacy Services, 340B solutions, EnlivenHealth retail pharmacy software, Inventory Optimization Service and the service portions of central pharmacy and IV compounding. Specialty Pharmacy drove growth while EnlivenHealth declined and was restructured in Q3 2025.

## Strategic priorities

- **Titan XT refresh cycle**: First Titan XT shipments were days away on October 29, 2026; management estimates the total replacement opportunity in excess of $2.5 billion on the installed base, hardware only.
- **OmniSphere cloud platform**: OmniSphere is the cloud-native layer unifying devices, data and workflows; general availability for ADS is targeted for the first half of 2027, with subscription pricing still being tested.
- **Competitive conversions**: Omnicell is pursuing customers of its primary competitor, using leasing on competitive deals; its first competitive Titan XT conversion came in Q2 2026.
- **EBITDA growing faster than revenue**: Leadership is ring-fencing refresh-cycle investment and cutting G&A and support costs; full-year 2026 non-GAAP EBITDA guidance was raised to $187-193 million.
- **Outpatient pharmacy growth**: Specialty Pharmacy Services and 340B solutions are the growth engine of SaaS and Expert Services, with new wins including a federally qualified health center.

## Latest results

In Q3 2026 total revenues were $307.9 million, down 1%, with product revenues of $173.1 million (-3%) on lower XTExtend volumes and service revenues of $134.8 million. Gross margin rose to 45% from 43% and net income to $11.0 million ($0.24 per diluted share) from $5.5 million. For the nine months revenues were $929.9 million (+7%) and net income $46.7 million, helped by a $14.0 million IEEPA tariff refund in Q2 2026. Guidance for full-year 2026 is revenue of $1.225-1.231 billion, ARR of $660-670 million, product bookings of $425-560 million and non-GAAP EBITDA of $187-193 million.

## Investments and deals

- **Capex and software development**: Capital expenditures were $40.4 million in 2025 plus $17.5 million of external-use software development; for the first nine months of 2026, capex was $32.7 million plus $8.8 million.
- **Share repurchases and debt**: Omnicell repurchased about 2,523,000 shares for $77.6 million in 2025 and repaid $175.0 million of convertible notes in September 2025; no repurchases were made in 2026.
- **Restructuring and portfolio focus**: Restructurings covered EnlivenHealth, Professional Services, the product organization, the Medimat line wind-down and the exit of the Beijing, China office; 2025 restructuring expense was $6.5 million.
- **Acquisitions**: There were no material acquisitions in 2024 or 2025; the company expects to keep seeking acquisitions of businesses, technologies or products.

## Challenges and risks

- **Bookings timing**: Sales cycles can exceed 12 to 24 months, and the low end of the bookings range reflects uncertainty around timing of purchasing decisions; the Titan XT announcement may also influence timing.
- **Memory chip costs**: Management estimated about $6 million of incremental memory cost in the second half of 2026, expected to persist for the foreseeable future.
- **Tariffs**: Section 301 tariffs replaced earlier tariffs, and possible Section 232 tariffs on medical equipment remain a risk; Omnicell mitigates through dual-sourcing and nearshoring.
- **340B and government payments**: 340B changes had a modest impact on 2026 ARR, and customers are preparing for lower government payments, including an expected $910 billion Medicaid spending reduction.
- **Competition**: Rivals with greater resources and larger installed bases launched new platforms in the same refresh cycle, and EnlivenHealth faces retail pharmacy industry dynamics.

## What leadership says

> "Customers are validating the potential value of combining Titan XT with OmniSphere, our cloud-native platform" — Randall A. Lipps, Chairman, CEO and Founder, Q3 2026 results press release, October 29, 2026

> "Leasing has become a meaningful part of our go-to-market approach on competitive deals" — Randall A. Lipps, Chairman, CEO and Founder, Q3 2026 earnings call, October 29, 2026

> "Reliable hardware and OmniSphere are not separable in our view." — Nnamdi Njoku, President and COO, Q3 2026 earnings call, October 29, 2026

> "Our EBITDA is growing meaningfully faster than revenue this year, even as top line growth remains modest" — Baird Radford, EVP and CFO, Q3 2026 earnings call, October 29, 2026


## Where a supplier can help

- **Semiconductor and component supply**: Tied to the memory chip cost and tariff challenges: alternative memory and component sources, and nearshored contract manufacturing, support the dual-sourcing strategy.
- **Cloud infrastructure and security**: Tied to the OmniSphere priority: cloud hosting, migration and healthcare security services help move customers from on-premise to cloud by the 2027 general availability.
- **Installation and field capacity**: Tied to the Titan XT refresh cycle: installation, logistics and field service partners help deploy hardware across a large installed base and in waves on large deals.
- **Lease financing partners**: Tied to the competitive conversions priority: finance companies can buy lease receivables, which Omnicell already sells to third parties, as leasing grows on competitive deals.
- **Cost efficiency in G&A**: Tied to the EBITDA priority: tools that automate support functions fit leadership's cuts outside innovation and go-to-market.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Omnicell Annual Report on Form 10-K for fiscal year 2025](https://www.sec.gov/Archives/edgar/data/926326/000092632626000006/omcl-20251231.htm)

Annual report · 2026-02-26

- Omnicell is a healthcare technology provider of medication management infrastructure (storage and dispensing automation powered by an intelligence ecosystem) built around the industry-defined vision of the Autonomous Pharmacy; it reports as a single segment.
- FY2025 total revenues were $1,184.8 million, up 7% from $1,112.2 million; product revenues $665.7 million (56%), service revenues $519.1 million (44%). Gross margin held at 42%; net income fell to $2.1 million ($0.04 per diluted share) from $12.5 million.
- Recurring business is growing: ARR reached $636 million at December 31, 2025 (vs $580 million); product bookings were $535 million (vs $558 million); total product backlog $640.3 million.
- Product growth came from XTExtend console swaps, offset by lower XT Series volumes ("as we are largely through the replacement cycle") and lower Central Pharmacy Dispensing Service products; services grew on technical services and Specialty Pharmacy Services, while EnlivenHealth revenues fell.
- Next-generation platform: Titan XT automated dispensing system integrated with OmniSphere, a cloud-native software and intelligence ecosystem; the company is migrating customers from on-premise to cloud infrastructure.
- About 90% of revenue is US; sales to members of the ten largest GPOs and federal agencies under the GSA Contract were about 61% of revenues; sales cycles can exceed 12 to 24 months.
- Customers' environment: the company cites the One Big Beautiful Bill Act ($910 billion Medicaid spending reduction), tariffs and labor shortages, and expects a shift from capital purchases to leasing, subscriptions and as-a-service models.
- Capital: repaid the remaining $175.0 million of 2025 convertible notes, repurchased about 2,523,000 shares for $77.6 million; cash fell to $196.5 million; $350.0 million undrawn revolver; $172.5 million 1.00% 2029 convertible notes outstanding.
- Restructuring in 2025: EnlivenHealth (about $2.6 million) and the continued wind-down of the Medimat Robotic Dispensing System (RDS) line (about $3.9 million); about 3,580 employees at year end.
- Leadership: Randall A. Lipps (founder, Chairman, President and CEO), Baird Radford (CFO since August 2025), Nnamdi Njoku (COO since October 2024), Corey J. Manley (Chief Legal and Administrative Officer).

### [Omnicell Quarterly Report on Form 10-Q for Q3 2026 (quarter ended September 30, 2026)](https://www.sec.gov/Archives/edgar/data/926326/000092632626000027/omcl-20260930.htm)

Interim report · 2026-11-04

- Q3 2026 total revenues $307.9 million, down 1% from $310.6 million; product revenues $173.1 million (-3%, lower XTExtend volumes partly offset by XT Series), service revenues $134.8 million (+1%).
- Nine months 2026 revenues $929.9 million, up 7% from $870.9 million; product revenues +8% on XT Series, partly offset by lower Central Pharmacy Dispensing and IV Compounding robotics revenue.
- Q3 gross margin rose to 45% from 43% (lower service costs after 2025 software upgrade expenses), despite higher semiconductor chip costs; nine-month gross margin 46% vs 43%, helped by a $14.0 million IEEPA tariff refund in Q2 2026.
- Q3 net income $11.0 million ($0.24 per diluted share) vs $5.5 million; nine-month net income $46.7 million vs $4.1 million.
- International share rising: 12% of Q3 revenues (vs 10%); rest of world revenue $36.0 million in Q3.
- Specialty Pharmacy Services keeps growing within SaaS and Expert Services, while EnlivenHealth and 340B portfolios declined.
- Cash $314.9 million at September 30, 2026 (vs $196.5 million at year end); nine-month operating cash flow $155.9 million; no buybacks in 2026 and the 2025 Repurchase Program concluded in Q2 2026.
- Headcount about 3,450 full-time employees; tariffs now Section 301 replacement tariffs at 10% or 12.5%, with a Section 232 medical devices investigation pending.

### [Omnicell Announces Third Quarter 2026 Financial Results (press release, 8-K Exhibit 99.1)](https://www.sec.gov/Archives/edgar/data/926326/000092632626000024/exhibit991q3-26.htm)

Interim report · 2026-10-29

- Q3 2026 total revenues were $308 million, down 1%; GAAP net income $11 million ($0.24 per diluted share); non-GAAP net income $27 million ($0.58); non-GAAP EBITDA $45 million vs $41 million.
- Revenue and profitability came in above the high end of guidance, supported by connected device demand, favorable product and service margins and disciplined cost management.
- Full-year 2026 guidance raised for profitability: non-GAAP EBITDA $187-193 million and non-GAAP EPS $2.48-2.56.
- Revenue guidance tightened to $1.225-1.231 billion (product $684-687 million, service $541-544 million); ARR $660-670 million; product bookings reiterated at $425-560 million.
- Q4 2026 guidance: revenues $295-301 million, non-GAAP EBITDA $30-36 million, non-GAAP EPS $0.41-0.49.
- CEO Randall Lipps cites "strong momentum with our next-generation platform, backed by a growing pipeline", with customers validating Titan XT combined with the cloud-native OmniSphere.
- Balance sheet: cash $315 million, total debt $169 million, total assets $2.1 billion, $350 million undrawn revolver; Q3 operating cash flow $33 million.
- Non-GAAP adjustments name restructurings in Professional Services, the product organization, EnlivenHealth and the exit of the Beijing, China office.

### [Omnicell Q3 2026 earnings call (corrected transcript)](https://s204.q4cdn.com/797010107/files/content_files/OMCL-Earnings-Transcript-October-29-2026.pdf)

Executive talk · Randall A. Lipps, Chairman, Chief Executive Officer & Founder (with Nnamdi Njoku, President & COO, and Baird Radford, CFO) · 2026-10-29

- Q3 2026 revenue $308 million and non-GAAP EBITDA $45 million, both above the top of guidance (revenue guide $301-307 million, EBITDA guide $32-37 million); non-GAAP EPS $0.58; free cash flow $20 million; cash $315 million.
- First Titan XT hardware shipments were "just days away"; OmniSphere general availability targeted for the first half of 2027, with attach rates expected to build over subsequent years.
- Management estimates the Titan XT replacement cycle opportunity "in excess of $2.5 billion" (hardware-only, installed base only, excluding share gains and OmniSphere).
- OmniSphere to be sold on a subscription model; pricing still being tested; CFO expects it "to punch above its weight from an EBITDA contribution perspective".
- 2026 product bookings guide kept at $425-560 million and back-end weighted; pipeline grew modestly and matured; competitive conversions take 9-12 months to reach revenue.
- Leasing is now a meaningful go-to-market tool on competitive deals; about 30% of the market leases, mostly customers of Omnicell's primary competitor.
- Profit focus: EBITDA growing much faster than revenue in 2026; full-year non-GAAP EBITDA guide raised to $187-193 million; about $6 million of second-half memory chip costs.
- Modest 2026 ARR impact expected from 340B dynamics; new specialty pharmacy contract with a federally qualified health center; VA wins in the government channel.

### [Omnicell Q2 2026 earnings call (corrected transcript)](https://s204.q4cdn.com/797010107/files/doc_financials/2026/q2/OMCL-Earnings-Transcript-July-30-2026.pdf)

Executive talk · Randall A. Lipps, Chairman, Chief Executive Officer & Founder (with Nnamdi Njoku, President & COO, and Baird Radford, CFO) · 2026-07-30

- Q2 2026 revenue $312 million (top of guidance); non-GAAP EBITDA $67 million and non-GAAP EPS $0.94, including a one-time $15 million tariff refund (EBITDA $52 million excluding it); GAAP EPS $0.52; free cash flow $56 million.
- Nnamdi Njoku appointed President and COO on July 1, 2026; Lipps stays Chairman and CEO with strategy unchanged.
- First competitive Titan XT conversion: a Southeast health system chose Titan XT with AWS, IV Workflow and other Omnicell solutions, with OmniSphere as "the linchpin".
- Installed-base Titan XT selections at an academic medical center in North Carolina, a Texas academic health system and an Arizona regional medical center; specialty pharmacy wins in Arizona, Oregon and Missouri.
- Full-year 2026 product bookings guidance cut at the low end to $425-560 million (top unchanged) on timing of medium and large deals; revenue guide $1.225-1.245 billion; ARR $660-680 million (consumables growth delayed); EBITDA guide raised to $175-185 million.
- Lipps: this is "the first refresh cycle in which both Omnicell and our largest competitor have introduced new platform offerings at the same time", lengthening evaluations but widening competitive opportunities.
- Memory chip shortage: about $6 million incremental cost in the second half of 2026, roughly 5 times the cost at the start of the year.
- IVX IV compounding robot still working through internal benchmarks before broader availability.

## Questions about Omnicell

### What does Omnicell do?

Omnicell sells medication dispensing automation, central pharmacy robotics, packaging consumables, software and services to hospitals and pharmacies, aiming at autonomous, zero-error medication management.

### What is Omnicell's revenue?

Total revenues were $1,184.8 million in 2025 (+7%). For 2026 the company guides revenue of $1.225-1.231 billion.

### How many employees does Omnicell have?

About 3,580 at December 31, 2025 and about 3,450 full-time at September 30, 2026.

### What is Omnicell's strategy?

It is driving a refresh of its installed base to Titan XT cabinets combined with the cloud-native OmniSphere platform, pursuing competitive conversions with leasing, and growing Specialty Pharmacy and 340B services.

### Who leads Omnicell?

Randall A. Lipps is Chairman, CEO and Founder; Nnamdi Njoku is President and COO; Baird Radford is EVP and CFO.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
